×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:SGEN

Seagen Stock Forecast, Price & News

$179.33
+5.33 (+3.06%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$173.54
$179.96
50-Day Range
$108.81
$179.33
52-Week Range
$105.43
$192.79
Volume
3.59 million shs
Average Volume
1.25 million shs
Market Capitalization
$33.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$164.55
30 days | 90 days | 365 days | Advanced Chart

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Stock Forecast (MarketRank)

Overall MarketRank

2.30 out of 5 stars

Medical Sector

275th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

42nd out of 216 stocks

Analyst Opinion: 2.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
Seagen logo

About Seagen (NASDAQ:SGEN)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

SGEN Stock News Headlines

Seagen (NASDAQ:SGEN) Sees Large Volume Increase
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
2,675
Year Founded
1998

Company Calendar

Last Earnings
4/28/2022
Today
6/24/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$164.92
High Stock Price Forecast
$208.00
Low Stock Price Forecast
$132.00
Forecasted Upside/Downside
-8.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63636363636364
Research Coverage
11 Analysts

Profitability

Net Income
$-674.47 million
Pretax Margin
-41.32%

Debt

Sales & Book Value

Annual Sales
$1.57 billion
Book Value
$16.76 per share

Miscellaneous

Free Float
133,823,000
Market Cap
$33.01 billion
Optionable
Optionable
Beta
0.85

Social Links















Seagen Frequently Asked Questions

Should I buy or sell Seagen stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Seagen stock.
View analyst ratings for Seagen
or view top-rated stocks.

What is Seagen's stock price forecast for 2022?

11 equities research analysts have issued 1-year price objectives for Seagen's stock. Their SGEN stock forecasts range from $132.00 to $208.00. On average, they predict Seagen's stock price to reach $164.92 in the next year. This suggests that the stock has a possible downside of 8.0%.
View analysts' price targets for Seagen
or view top-rated stocks among Wall Street analysts.

How has Seagen's stock performed in 2022?

Seagen's stock was trading at $154.60 at the start of the year. Since then, SGEN stock has increased by 16.0% and is now trading at $179.33.
View the best growth stocks for 2022 here
.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Seagen
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings results on Thursday, April, 28th. The biotechnology company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.24. The biotechnology company earned $426.50 million during the quarter, compared to the consensus estimate of $401.75 million. Seagen had a negative trailing twelve-month return on equity of 21.86% and a negative net margin of 41.32%. The firm's revenue for the quarter was up 28.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.67) earnings per share.
View Seagen's earnings history
.

What guidance has Seagen issued on next quarter's earnings?

Seagen updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.67 billion-$1.75 billion, compared to the consensus revenue estimate of $1.78 billion.

Who are Seagen's key executives?

Seagen's management team includes the following people:
  • Dr. Roger D. Dansey M.D., Chief Medical Officer & Interim CEO (Age 66, Pay $1.53M) (LinkedIn Profile)
  • Dr. Clay B. Siegall Ph.D., Co-Founder, Chairman, Pres & CEO (Leave of Absence) (Age 61, Pay $3.09M)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 61, Pay $1.17M)
  • Ms. Jean I. Liu J.D., M.S., Chief Legal Officer (Age 54, Pay $1.11M) (LinkedIn Profile)
  • Mr. Charles R. Romp, Exec. VP of Commercial U.S. (Age 54, Pay $1.02M) (LinkedIn Profile)
  • Dr. Vaughn B. Himes Ph.D., Chief Technical Officer (Age 61)
  • Peggy Pinkston, Sr. VP of Investor Relations
  • Mr. David Caouette, VP of Corp. Communications
  • Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. & Alliance Management (Age 50)
  • Mr. Matt Skelton, VP of Marketing

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital International Investors (8.40%), BlackRock Inc. (7.44%), Wellington Management Group LLP (6.78%), Vanguard Group Inc. (6.67%), Primecap Management Co. CA (2.51%) and State Street Corp (1.92%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Lip Bu Tan, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends for Seagen
.

Which institutional investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Bank of America Corp DE, Mirae Asset Global Investments Co. Ltd., Mirae Asset Global Investments Co. Ltd., TD Asset Management Inc., UBS Group AG, First Trust Advisors LP, and Tobam. Company insiders that have sold Seagen company stock in the last two years include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which institutional investors are buying Seagen stock?

SGEN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Woodline Partners LP, BlackRock Inc., Capital Group Private Client Services Inc., Eagle Health Investments LP, Artal Group S.A., and Vanguard Group Inc..
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $179.33.

How much money does Seagen make?

Seagen (NASDAQ:SGEN) has a market capitalization of $33.01 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674.47 million in net income (profit) each year or ($3.770010) on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,675 workers across the globe.

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More

When was Seagen founded?

Seagen was founded in 1998.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for Seagen is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at [email protected], or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 6/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.